RS 39604

Drug Profile

RS 39604

Latest Information Update: 27 Nov 2006

Price : $50

At a glance

  • Originator Roche Palo Alto LLC
  • Class
  • Mechanism of Action Serotonin 4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Irritable bowel syndrome

Most Recent Events

  • 03 Nov 1998 No-Development-Reported for Irritable bowel syndrome in USA (PO)
  • 13 Mar 1996 New profile
  • 13 Mar 1996 Preclinical development for Irritable bowel syndrome in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top